According to this First Global Consensus, WHO strongly endorsed cytokine therapy (G-CSF or GM-CSF) within 24 h of exposure, above 2 Gy, for affected individuals with significant lymphopenia or when neutropenia (<500 cells/mm3) persists for more than 7 days [236,255]. This evidence concerns the gene CSF3 and neutropenia.